To evaluate the efficacy and safety of intensive dose of rosuvastatin, 40 mg/day, initiated early and continued for 12 weeks, in 'very high' risk or 'high' risk patients, according to NCEP ATP III guidelines, in Indian patients.

Trial Profile

To evaluate the efficacy and safety of intensive dose of rosuvastatin, 40 mg/day, initiated early and continued for 12 weeks, in 'very high' risk or 'high' risk patients, according to NCEP ATP III guidelines, in Indian patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease
  • Focus Therapeutic Use
  • Sponsors Ranbaxy Laboratories
  • Most Recent Events

    • 28 Jul 2014 Status changed from recruiting to active, no longer recruiting, as per Clinical Trials Registry - India record.
    • 25 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top